REG - Venture Life Group - Director/PDMR Shareholding

Venture LifeAnnouncement

Yesterday 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260109:nRSI3640Oa&default-theme=true

RNS Number : 3640O  Venture Life Group PLC  09 January 2026

9 January 2026

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Company")

 

Director/PDMR Shareholding

Further to the announcement on 2 January 2026 of the exercise of options over
483,333 ordinary shares of 0.3 pence each in the capital of the Company
("Ordinary Shares") by Jerry Randall (Chief Executive Officer), the Company
has been notified that, in order to satisfy the payment of the exercise price
of the options and the personal tax liabilities resulting from the exercise of
the options, Jerry Randall has sold 387,705 Ordinary Shares at a
volume-weighted average price of 66.22 pence per Ordinary Share ("the "Share
Sale").

Following the Share Sale, Jerry Randall beneficially holds 2,348,828 Ordinary
Shares representing approximately 1.82 per cent. of the Company's issued share
capital.

 

For further information, please contact:

Venture Life Group
PLC
                +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

The Company makes the following disclosure in accordance with article 19(3) of
the Market Abuse Regulation:

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Jerry Randall

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908
 b)   Nature of the transaction                                    Sale of Ordinary Shares

 c)   Price(s) and volume(s)

Price         Volume
                                                                   66.50 pence   100,000

                                                                   66.50 pence   54,690

                                                                   66.90 pence   10,000

                                                                   66.00 pence   50,000

                                                                   66.00 pence   173,015

 d)   Aggregated information                                       -       387,705 Ordinary Shares

                                                                   -       66.22 pence

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      7 / 8 / 9 January 2026

 f)   Place of the transaction                                     London Stock Exchange

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

-       387,705 Ordinary Shares

-       66.22 pence

 

 

 

 

 

 

e)

 

Date of the transaction

 

7 / 8 / 9 January 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFFLLEIAIIR



            Copyright 2019 Regulatory News Service, all rights reserved